At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 18 enrolled
Drug / intervention
Probenecid +6 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomised, Open-label, Three-way Crossover Trial to Investigate the Effect of Rifampicin and Probenecid on Empagliflozin Pharmacokinetics in Healthy Male and Female Subjects
In Brief
A Phase 1 clinical trial evaluating Probenecid, Rifampicin, and 2 other interventions for Healthy. Completed, enrolled 18 participants across 1 site.
Detailed Summary
The objectives of the trial are to investigate the effect of concurrent administration of rifampicin and probenecid on the pharmacokinetics of empagliflozin.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesGermany
Collaborators--
Timeline
Phase 1CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2012
First PostedJul 2012
Primary CompletionAug 2012
TodayJul 2026
First PostedJul 6, 2012
Enrollment StartJun 1, 2012
Primary CompletionAug 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 14.0 years ago
Interventions
Probeneciddrug
Probenecid
Rifampicindrug
Rifampicin
Empagliflozindrug
BI Drug
Empagliflozindrug
BI Drug
Rifampicindrug
Rifampicin
Probeneciddrug
Probenecid
Empagliflozin (BI 10773)drug
BI Drug